Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

280P - Safety and efficacy of concurrent chemoradiotherapy for head and neck cancers in younger versus older patients: Post hoc analysis of a randomized control trial


22 Nov 2020


e-Poster Display Session


Vanita Noronha


Annals of Oncology (2020) 31 (suppl_6): S1347-S1354. 10.1016/annonc/annonc360


V. Noronha, G.K. Singh, V.M. Patil, N. Menon, A.S. Joshi, K. Prabhash

Author affiliations

  • Medical Oncology Department, Tata Memorial Hospital - Tata Memorial Centre, 400012 - Mumbai/IN

Abstract 280P


Head and neck squamous cell carcinoma (HNSCC) is a well-known malignancy in the older population. However, there is scarcity of data on the effect of chemoradiation on them. We did a posthoc analysis of a randomized study conducted at our institution to understand this effect.


We did a posthoc analysis of the study where the patients received chemoradiation. The database of this study was used for the present analysis. We evaluated the differences in demography, grade 3 or worse adverse events, compliance of treatment, loco-regional control (LRC), progression free survival (PFS) and overall survival (OS) between older (≥ 60 years) and the younger patients.


Out of 300 patients, 283 (94.3%) comprised the younger cohort (age < 60 years) while the older cohort included 17 (5.7%) patients. There was no difference in the occurrence of severe (grade 3/4) toxicities in the older cohort when compared to the younger patients. At a median follow up period of 22 months (range, 3-51), the cumulative LRC at 2 years was 67.1% and 100% in younger and the older group respectively (P = 0.018). The estimated median PFS in younger patients was 24.4 months (95% CI, 12.5 to 36.3), while it was not reached in the older group (P = 0.53). The estimated median OS was 41.3 months in the younger and not reached in the older group (P = 0.613).


Older patients with locally advanced HNSCC who received radical concurrent cisplatin-based chemoradiotherapy showed significantly better LRC. Older patients experienced similar adverse events as compared to the younger ones.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings